Ironwood Pharmaceuticals and Forest Laboratories have announced the availability of guanylate cyclase-C (GC-C) agonist, Linzess across the US pharmacies.
The FDA approved, once-daily, oral product is indicated for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Linzess was designed to act locally in the intestine and to offer relief from the abdominal pain and constipation coupled with IBS-C and constipation and hard stools due to CIC.
The 290mcg dose of Linzess is recommended for IBS-C patients while 145mcg is recommended for CIC patients.
Linzess works by binding to GC-C receptor locally, resulting in increased intestinal fluid secretion and visceral pain reduction.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/ironwood-linzess-drug-available-in-us-pharmacies-191212
